BAL 101553

Drug Profile

BAL 101553

Alternative Names: BAL-101553; BAL-27862

Latest Information Update: 08 Jul 2017

Price : $50

At a glance

  • Originator Basilea Pharmaceutica
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioblastoma
  • Preclinical Brain cancer; Breast cancer

Most Recent Events

  • 12 Jun 2017 Basilea Pharmaceutica, in collaboration with the Adult Brain Tumor Consortium, plans a phase I trial for Glioblastoma (Combination therapy, Newly diagnosed) in USA, in third quarter of 2017
  • 12 Jun 2017 Basilea Pharmaceutica signs a clinical study agreement with the Adult Brain Tumor Consortium in USA
  • 06 Jun 2017 Interim efficacy data from a phase I/IIa trial in Solid tumours presented at the 53rd Annual meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top